Discovery of a Novel Hsp90 Inhibitor by Fragment Linking
John J. Barker, Oliver Barker, Stephen M. Courtney et al. · ChemMedChem · 2010
Hooking up! Hsp90 is a molecular chaperone involved in the stabilisation of numerous client proteins including those involved in oncogenic transformations. Through a high-throughput biochemical fragment screen, we have identified novel fragment inhibitors of Hsp90. Two fragment hits were combined to give a dual-fragment Hsp90 complex, and the following successful fragment-linking resulted in a 1000-fold improvement in activity.
Cited by 51 works. doi:10.1002/cmdc.201000219
Authors
- John J. Barker
- Oliver Barker
- Stephen M. Courtney
- Mihaly Gardiner
- Thomas Hesterkamp
- Osamu Ichihara
- Owen C. Mather
- Christian Montalbetti
- Annett Müller
- Mario Varasi
- Mark A. Whittaker
- Christopher J. Yarnold
References
- Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent
- Ligand efficiency: a useful metric for lead selection
- On the attribution and additivity of binding energies
- Fragment molecular orbital method: an approximate computational method for large molecules
- High-throughput crystallography for lead discovery in drug design
- A decade of fragment-based drug design: strategic advances and lessons learned
- Fragment-based lead discovery
- Recent Developments in Fragment-Based Drug Discovery
- Fragment-based lead discovery: leads by design
- Extending the Power of Quantum Chemistry to Large Systems with the Fragment Molecular Orbital Method